Hal Barron at Endpoints News' UKBIO 2019
February 5, 2020 07:53 AM ESTUpdated 04:57 PM
R&D

Glax­o­SmithK­line's lat­est makeover in­cludes auc­tion­ing off der­ma­tol­ogy, adding new tech and lay­offs. But how many?

John Carroll

Editor & Founder

GSK ex­ecs an­nounced Wednes­day morn­ing that they are set­ting up a 2-year pro­gram to pre­pare the com­pa­ny for its split in two — con­sumer health­care and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times